Core Viewpoint - The article discusses the achievements and future plans of China's medical insurance system during the "14th Five-Year Plan" period, highlighting improvements in coverage, fund management, and the introduction of long-term care insurance [1][3]. Group 1: Medical Insurance Coverage - The national basic medical insurance coverage rate remains stable at around 95%, with a cumulative expenditure of 12.13 trillion yuan, averaging an annual growth rate of 9.1% [1][3]. - By 2024, the number of people covered by basic medical insurance is expected to reach 1.327 billion, with long-term care insurance coverage at 190 million [1][3]. - The direct settlement rate for cross-provincial medical expenses exceeds 90%, and the national medical insurance drug list has been unified, totaling 3,159 types of drugs [1][3]. Group 2: Long-Term Care Insurance - The long-term care insurance system is expected to be implemented nationwide soon, as the current pilot programs have shown positive results [4][7]. - As of June 2025, 253 million people are participating in maternity insurance, with cumulative expenditures of 438.3 billion yuan, benefiting 96.14 million people [6]. - The long-term care insurance aims to alleviate the financial burden of daily care for elderly individuals who have lost their ability to care for themselves, addressing the increasing demand for elderly care services [6][7]. Group 3: Fund Management and Regulation - The medical insurance fund is under increasing pressure, and the focus will be on ensuring fund safety and risk assessment during the "15th Five-Year Plan" period [4][8]. - The reform of payment methods has transitioned from a "post-payment" to a "pre-payment" system, promoting efficiency in medical institutions and reducing patient out-of-pocket expenses by approximately 5% year-on-year [9][10]. - The National Medical Insurance Administration has intensified efforts to combat fraud and misuse of medical insurance funds, recovering 16.13 billion yuan in the first half of the year through inspections of 335,000 medical institutions [10][11]. Group 4: Drug Price Governance - The article emphasizes the importance of drug price governance, with the government supporting market-driven pricing while also maintaining oversight to prevent price manipulation [12][13]. - Since 2018, the government has conducted 10 rounds of centralized drug procurement, covering 435 types of drugs, which has helped lower drug prices and improve accessibility [13][14]. - The National Medical Insurance Administration is committed to ensuring fair pricing practices and encourages public reporting of unusually high drug prices [14].

Group 1 - The National Medical Insurance Administration (NMIA) has intensified the regulation of medical insurance funds by holding individuals accountable for violations, marking a shift from solely punishing institutions to also targeting responsible personnel [1][2] - A case in Jiangxi Province highlighted this approach, where individuals involved in fraudulent activities were penalized with points against their medical insurance payment qualifications, indicating a more stringent accountability system [1] - The introduction of a point-based management system for medical insurance payment qualifications aims to enhance the precision and deterrent effect of regulatory measures, extending oversight to specific individuals within medical institutions [2][3] Group 2 - The regulatory framework emphasizes a balanced approach, combining education and punishment, with mechanisms in place to protect the rights of medical personnel while ensuring accountability [3] - Various provinces have implemented dynamic responsibility recognition mechanisms to ensure that accountability is accurately assigned, preventing generalized or superficial handling of violations [3] - The overarching goal is to ensure the proper and compliant use of medical insurance funds, which are critical for the health and well-being of over 1.3 billion insured individuals in the country [2][3]

Policy Developments - The National Healthcare Security Administration (NHSA) has initiated the 11th batch of centralized procurement, optimizing the selection rules by no longer solely relying on the lowest bid as a reference. Companies with the lowest bids must now justify the reasonableness of their pricing and ensure it does not fall below cost [2] Drug and Medical Device Approvals - Senxuan Pharmaceutical's subsidiary has received approval for the market launch of Ritonavir raw materials, an antiviral drug primarily used for treating AIDS and also utilized during the COVID-19 pandemic [4] - Hengrui Medicine's subsidiary has received a clinical trial approval notice for the injectable HRS8179 drug, aimed at preventing severe brain edema after large-scale cerebral infarction. The project has seen a cumulative R&D investment of approximately 47.4 million yuan [5] Financial Reports - Sino Medical anticipates a 296.54% year-on-year increase in net profit for the first half of 2025, with expected revenue of 240 million yuan, reflecting a 12.53% growth [7] - WuXi Biologics forecasts a revenue growth of about 16% for the first half of the year, with profits expected to increase by approximately 54% and 56% for the company and its equity shareholders, respectively [8] Capital Markets - Lianhuan Pharmaceutical plans to issue up to 500 million yuan in technology innovation bonds to enhance R&D capabilities and optimize its debt structure. The bonds will be publicly issued with a term of no more than three years [10] Industry Developments - The NHSA has reported that over 100 drug varieties have applied to be included in the commercial health insurance innovative drug directory, which aims to incorporate high-value innovative drugs that cannot yet be included in the basic medical insurance directory [12] - As of the end of 2024, the cumulative recovery of medical insurance funds has reached 104.5 billion yuan, with a total balance of 3.86 trillion yuan in the insurance fund [14]

Core Insights - The article discusses the significant advancements and reforms in China's medical insurance system during the "14th Five-Year Plan" period, emphasizing the focus on improving public health and reducing medical costs for citizens [1][2]. Group 1: Medical Insurance Coverage - By 2024, the number of people covered by basic medical insurance is expected to reach 1.327 billion, with a stable participation rate of around 95% during the "14th Five-Year Plan" [1][2]. - Nearly 20 billion medical insurance reimbursements are anticipated from 2021 to 2024, with 2024 figures projected to be 1.6 times that of 2020 [2]. Group 2: Support for Specific Demographics - As of June this year, 253 million people are enrolled in maternity insurance, with cumulative expenditures reaching 438.3 billion yuan, benefiting over 96.14 million instances [2]. - The long-term care insurance system is being established, with 190 million participants expected by the end of 2024, and over 95% of village clinics included in the insurance network [2]. Group 3: Healthcare Accessibility and Efficiency - The number of designated medical institutions for insurance has reached 1.1 million, and the direct settlement rate for cross-province hospitalizations is around 90% [3][5]. - The implementation of a unified national medical insurance information platform has improved service efficiency, with over 1.236 billion people using medical insurance codes for direct settlement [4][5]. Group 4: Fund Security and Regulation - The cumulative recovery of medical insurance funds has reached 104.5 billion yuan during the "14th Five-Year Plan," with a total fund balance of 3.86 trillion yuan expected by the end of 2024 [6][7]. - The National Medical Insurance Bureau has intensified supervision and regulation, conducting inspections on 335,000 medical institutions and recovering 16.13 billion yuan in funds in the first half of this year [6][7].

Core Viewpoint - The article emphasizes the ongoing reforms in China's medical insurance system during the "14th Five-Year Plan" period, focusing on reducing the financial burden on citizens and enhancing the regulatory framework for medical insurance funds [1]. Group 1: Medical Insurance Coverage - The national basic medical insurance coverage rate remains stable at around 95%, with an expected 1.327 billion people insured by 2024 [2]. - Nearly 200 billion medical visits have been reimbursed through insurance from 2021 to 2024, benefiting 3.5 billion low-income individuals through medical assistance programs [2]. Group 2: Support for Vulnerable Groups - Measures have been implemented to enhance support for children and the elderly, including the establishment of a long-term care insurance system, with 190 million participants expected by the end of 2024 [3]. - The maternity insurance program has seen participation from 253 million individuals, with over 96 million enjoying benefits [3]. Group 3: Financial Impact of Medical Insurance - Cumulative medical insurance fund expenditures reached 12.13 trillion yuan, with an annual growth rate of 9.1% [4]. - Spending on innovative drugs has significantly increased, with 2024 expenditures projected to be 3.9 times that of 2020, reflecting a 40% annual growth rate [4]. Group 4: Reducing Medical Costs - Policies have reduced the financial burden on low-income rural populations by over 650 billion yuan during the "14th Five-Year Plan" [5]. - A total of 402 new drugs have been added to the insurance coverage list, and price regulation efforts have standardized over 27,000 drug specifications [5]. Group 5: Enhancements in Medical Services - Cross-province medical services have been improved, allowing for direct settlement of outpatient chronic disease treatments for 10 types of conditions [7]. - The establishment of a "15-minute medical service circle" aims to enhance accessibility, with over 1.236 billion people using medical insurance codes for direct settlement [7]. Group 6: Fund Security and Regulation - The cumulative balance of the medical insurance fund reached 3.86 trillion yuan by the end of 2024, with ongoing monitoring to ensure stable operations [8]. - Innovative regulatory measures, including big data analysis, have led to the recovery of 10.45 billion yuan in misused funds [8][9].

Core Viewpoint - The article highlights the achievements and future plans of China's medical insurance system during the "14th Five-Year Plan" period, emphasizing the stability and expansion of coverage, the financial support for the healthcare industry, and the ongoing reforms to improve the quality and efficiency of medical services [1][2]. Group 1: Medical Insurance Coverage and Financial Support - The basic medical insurance coverage rate has remained stable at around 95%, with 1.327 billion people enrolled in 2024 [1][3]. - Cumulative medical insurance fund expenditure reached 12.13 trillion yuan, with an annual growth rate of 9.1%, providing robust financial support for healthcare services [1][2]. - Nearly 200 billion medical insurance reimbursements were utilized by patients from 2021 to 2024, marking a 1.6 times increase compared to 2020 [3]. Group 2: Multi-tiered Medical Security System - A multi-tiered medical security system is being established, consisting of a unified medical insurance information platform, basic medical insurance, critical illness insurance, and medical assistance [4]. - As of June 2025, 253 million people participated in maternity insurance, with cumulative expenditures of 438.3 billion yuan [4]. - Long-term care insurance has covered 190 million people, addressing the care needs of disabled individuals [5]. Group 3: Regulation and Management of Medical Insurance Funds - The National Medical Insurance Administration has intensified efforts to regulate medical insurance funds, focusing on reducing fraud and ensuring proper fund usage [6][7]. - In the first half of the year, 335,000 medical institutions were inspected, recovering 16.13 billion yuan in misused funds [7]. - The administration has implemented data-driven approaches to enhance the precision of fund management and fraud detection [7]. Group 4: Drug Price Governance - Drug pricing remains a significant concern, with the government encouraging market-driven pricing while maintaining oversight to prevent price manipulation [9][10]. - Since 2018, ten rounds of centralized drug procurement have been conducted, covering 435 drugs, which has helped lower drug prices and improve accessibility [11]. - The administration has taken measures to address abnormal drug pricing, urging companies to adhere to fair pricing practices [12].

Core Viewpoint - The medical insurance system in Dezhou has shown significant progress in the first half of 2025, with various initiatives enhancing the public's sense of security regarding medical insurance [3][4][12]. Group 1: Medical Insurance Fund Performance - In the first half of 2025, the total income of the city's medical insurance fund was 3.886 billion, while total expenditure reached 4.607 billion, resulting in a cumulative balance of 7.352 billion [4]. - The employee medical insurance fund generated an income of 2.349 billion, a year-on-year increase of 6.68%, with expenditures of 1.991 billion, up 3.54% [4]. - The resident medical insurance fund had an income of 1.537 billion and expenditures of 2.616 billion, with a budget execution rate of 54.81% [4]. Group 2: Healthcare Reform and Initiatives - The city has implemented a "Three Medical Linkage + Traditional Chinese Medicine" reform, resulting in savings of 755 million from drug and consumable procurement [5]. - The "Dezhou Huimin Bao" commercial insurance program has seen participation from 334,800 individuals by the end of June [5]. - The city has expanded the number of designated medical institutions for traditional Chinese medicine from 81 to 115 [5]. Group 3: Service Capability Enhancement - The medical insurance settlement process has been optimized, reducing the settlement cycle to 15 working days [6]. - The city aims to cover 5.074 million insured individuals by 2025, with an additional 49,500 new participants this year [6]. - The online processing of medical expense reimbursements reached 12.2045 million cases in the first half of the year [6]. Group 4: Fund Supervision and Management - The city recovered and returned 22.1135 million in medical insurance funds and imposed administrative penalties totaling 3.4545 million in the first half of the year [8]. - A credit and joint supervision system has been established to manage the qualifications of personnel in designated medical institutions [9]. Group 5: Ongoing Reforms and Innovations - The city has implemented reforms in major disease medical insurance and assistance systems, benefiting 110,100 individuals with a total expenditure of 43.0352 million [10]. - The average hospitalization cost has decreased by 6.57% compared to the previous year, with personal hospitalization burdens reduced by 6.84% [10]. - The city has introduced a unified major disease insurance fund, saving 85 million in resident fund expenditures [11]. Group 6: Future Directions - The medical insurance bureau plans to continue deepening reforms and ensuring comprehensive coverage for the population, aiming to enhance the quality of medical insurance services [12].

Core Insights - The "14th Five-Year Plan" aims to enhance the national medical insurance system, achieving a stable coverage rate of approximately 95% and a cumulative expenditure of 12.13 trillion yuan, with an annual growth rate of 9.1% [1][3] Group 1: Medical Insurance Coverage - By 2024, nearly 200 million medical visits will benefit from insurance reimbursement, representing a 1.6 times increase compared to 2020 [3] - As of June 2025, 253 million people are expected to participate in maternity insurance, with cumulative expenditures reaching 438.3 billion yuan and benefits enjoyed by 96.14 million people [3] Group 2: Long-term Care and Elderly Support - A long-term care insurance system is being established, with 190 million participants expected by the end of 2024, addressing the needs of disabled individuals [3] - Over 95% of village clinics will be included in the insurance system, facilitating access to medical services for the elderly [3] Group 3: Medical Institutions and Cross-Province Services - By June 2025, the number of designated medical institutions for insurance will reach 1.1 million, expanding the coverage of employee insurance to include close relatives [4] - The number of cross-province designated medical institutions has reached 644,000, benefiting 560 million medical visits and reducing out-of-pocket expenses by 590 billion yuan [4] Group 4: Support for New Medical Technologies - A total of 402 new drugs have been added to the insurance catalog since the beginning of the "14th Five-Year Plan," with ongoing reforms in payment methods to promote new technologies and equipment in clinical applications [4] Group 5: Poverty Alleviation and Future Directions - Medical assistance policies have benefited 673 million rural low-income individuals, alleviating over 650 billion yuan in medical expenses [5] - The National Medical Insurance Administration aims to manage insurance funds effectively while supporting the development of the pharmaceutical industry and enhancing the availability of safe and efficient medical products and services [5]

Group 1: Healthcare Insurance and Coverage - The national basic medical insurance coverage rate remains stable at around 95%, with an expected 1.327 billion people insured by 2024, representing a 1.6 times increase from 2020 [1][3] - Cumulative expenditure of the medical insurance fund during the 14th Five-Year Plan period reached 12.13 trillion yuan, with an annual growth rate of 9.1% [1] - The multi-tiered medical security system is being established, including basic medical insurance, serious illness insurance, and medical assistance [3] Group 2: Long-term Care Insurance - As of June 2025, 253 million people are expected to participate in maternity insurance, with cumulative expenditures of 438.3 billion yuan [3][4] - The long-term care insurance system aims to alleviate the financial burden of daily care for the elderly and disabled individuals [3][4] Group 3: Medical Fund Management and Regulation - The National Medical Insurance Administration is enhancing the regulation of medical insurance funds to combat fraud and misuse, with 335,000 medical institutions inspected in the first half of the year, recovering 16.13 billion yuan [7] - The transition from a "post-payment" to a "pre-payment" system is being implemented, promoting efficiency in medical institutions and reducing patient out-of-pocket expenses by approximately 5% year-on-year [6] Group 4: Drug Price Governance - The 11th batch of centralized drug procurement has been initiated, emphasizing principles such as maintaining clinical stability and ensuring quality [9] - Since 2018, 10 batches of drug procurement have been conducted at the national level, covering 435 types of drugs, which has helped lower drug costs and improve accessibility [9]

21世纪经济报道记者 贺佳雯 北京报道 在推进科技赋能方面，全国统一的医保信息平台全面建成，医保业务编码标准全国统一，医保智能管理水平显著提升。医保码、移动支付和电子处方全面应 用，群众就医购药更加便捷。跨省异地就医直接结算人次从2020年的537万人次增加到2024年的2.38亿人次，增长了44倍，跨省异地就医住院费用直接结算 率超过了90%。 二是医保支付流程更加高效。近年来，医保基金支出持续稳定增长，不仅为广大参保群众的生命健康提供了坚实保障，也为医疗机构的发展提供了重要支 撑。 在推进协同发展方面，建立多层次医疗保障体系，医保各项改革持续赋能医疗机构和医药产业高质量发展。即时结算、直接结算、同步结算稳步推进。国家 医保药品目录实现了全国统一，目录内药品总数达到了3159种。医保支付方式不断完善。药品、医用耗材集中带量采购常态化制度化运行。医疗服务价格改 革试点有序推进，医疗服务价格动态调整机制全面建立。 南方财经·21世纪经济报道记者提问：深化医保支付方式改革是提高医疗资源使用效率的重要举措。国家医保局如何通过这些改革，引导医疗机构从"规模扩 张"转向"提质增效"，更好地满足人民群众看病就医的需求？ ...